Life Cycle of A Block Buster Drug

Barry A. Berkowitz, PhD, is Corporate Vice President, Albany Molecular Research, Inc. and Scientist in Residence at Northeastern University. He has held both research and executive positions at the Roche Institute of Molecular Biology and SmithKline, and was Founder and Chief Executive Officer of several biotechnology companies: Magainin (now Genaera); Myco/Chemgenics (acquired by Millennium); Strong Pharmaceuticals (now Fibrogen); and New Chemical Entities (acquired by Albany Molecular Research). He continues to enjoy drug discovery and the development of people, companies, and ideas. E-mail strongpharmaceuticals{at}

This Article

  1. MI February 2002 vol. 2 no. 1 6-11